Publications

Take a deeper look into all the publications produced by researchers at The Dartmouth Institute.

Barr PJ, Berry SA, Gozansky WS, McQuillan DB, Ross C, Carmichael D, Austin AM, Satterlund TD, Schifferdecker KE, Council L, Dannenberg MD, Wampler AT, Nelson EC, Skinner J

2020 Mar 2;4(1):17doi: 10.1186/s41687-020-0183-5

It is unclear whether data from patient-reported outcome measures (PROMs) are captured and used by clinicians despite policy initiatives. We examined the extent to which fall risk and urinary incontinence (UI) reported on PROMS and provided to clinicians prior to a patient visit are subsequently captured in the electronic medical record (EMR). Additionally, we aimed to determine whether the use of PROMs and EMR documentation is higher for visits where PROM data was provided to clinicians.

J Patient Rep Outcomes|2020 Mar 2

Schroeck FR, St Ivany A, Lowrance W, Makarov DV, Goodney PP, Zubkoff L

2020 Mar 2;:JOP1900576doi: 10.1200/JOP.19.00576

Many patients living with bladder cancer do not undergo surveillance that is aligned with their risk for recurrence or progression, which exposes them to unnecessary risk and burden of procedures. To implement risk-aligned surveillance as recommended by multiple guidelines, we need to understand patient-, provider-, and system-level factors contributing to the delivery of risk-aligned surveillance. In this study, we sought to systematically assess patient-level factors.

JCO Oncol Pract|2020 Mar 2

Wang ME, Shaughnessy EE, Leyenaar JK

2020 Feb 11;15(2):E1-E3doi: 10.12788/jhm.3373

J Hosp Med|2020 Feb 11

Miano TA, Yang W, Shashaty MGS, Zuppa A, Brown JR, Hennessy S

2020 Feb 29;doi: 10.1002/cpt.1819

Amiodarone inhibits warfarin metabolism and is associated with major bleeding during warfarin therapy. Managing this drug-drug interaction (DDI) is challenging because of substantial interpatient variability in DDI magnitude. Because renal dysfunction induces changes in drug metabolism and protein binding that could alter cytochrome P450 inhibition mechanisms, we hypothesized that renal dysfunction alters the impact of the warfarin-amiodarone DDI. We tested this question in a propensity-matched cohort study of hospitalized patients with atrial fibrillation. Patients were queried from an electronic health record database. Renal function was estimated with creatinine clearance (CrCl). Warfarin response was measured with the warfarin sensitivity index (WSI), a dose-normalized international normalized ratio (INR) measure, and was modeled with multilevel mixed-effects linear regression. Time to supratherapeutic INR (>4) was modeled using Cox regression. Propensity score matching resulted in 4518 amiodarone patients and 4518 controls. Amiodarone's effect on warfarin response varied three-fold across the renal function range, increasing WSI by 36% in patients with normal renal function (CrCl 115 ml/min), but by only 11.8% in patients with severe renal dysfunction (CrCl 15 ml/min). Similarly, amiodarone had a strong effect in patients with normal renal function, HR 1.80 (1.23,2.64), but a negligible effect on supratherapeutic INR hazard in patients with severe renal dysfunction, HR 1.01 (0.75,1.37). These results suggest that renal function is a novel factor that explains substantial variability in the warfarin-amiodarone DDI. This information could inform warfarin dosage adjustment and monitoring, and may have implications for the selection of oral anticoagulation agents in patients treated with amiodarone.

Clin Pharmacol Ther|2020 Feb 29

Schroeder GD, Radcliff KE, Vaccaro AR, Murphy H, Sutton RM, Lurie JD, Zhao W, Hilibrand AS

2020 Mar;33(2):82-88doi: 10.1097/BSD.0000000000000887

A retrospective cohort study.

Clin Spine Surg|2020 Mar

Dakour-Aridi H, Mathlouthi A, Locham S, Goodney P, Schermerhorn ML, Malas MB

2020 Feb 18;pii: S0741-5214(19)32310-9. doi: 10.1016/j.jvs.2019.07.100

Restenosis after carotid revascularization is clinically challenging. Several studies have looked into the management of recurrent restenosis; however, studies looking into factors associated with restenosis are limited. This study evaluated the predictors of restenosis after carotid artery stenting (CAS) and carotid endarterectomy (CEA) using a large national database.

J Vasc Surg|2020 Feb 18

Wanken ZJ, Anderson PB, Bessen SY, Rode JB, Columbo JA, Trooboff SW, Moore KO, Goodney PP

2020 Feb 17;pii: S0741-5214(19)32502-9. doi: 10.1016/j.jvs.2019.09.040

To effectively use administrative claims for healthcare research, clinical events must be inferred from coding data according to validated algorithms. In October 2015, the United States transitioned from the International Classification of Diseases Ninth Revision (ICD-9) to the Tenth Revision (ICD-10). We describe our method to derive new ICD-10 codes for outcomes after vascular procedures from our prior, validated ICD-9 codes.

J Vasc Surg|2020 Feb 17

Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Scherer E, Marsch LA

2020 Apr;111:54-66doi: 10.1016/j.jsat.2020.01.009

Treatment for opioid use disorders has recently evolved to include long-acting injectable and implantable formulations of medications for opioid use disorder (MOUD). Incorporating patient preferences into treatment for substance use disorders is associated with increased motivation and treatment satisfaction. This study sought to assess treatment preferences for long-acting injectable and implantable MOUD as compared to short-acting formulations among individuals with OUD.

J Subst Abuse Treat|2020 Apr

Close

Get the latest updates on applying to Dartmouth

Loading...